Home | Site Map | Contact
You are here: Home » PBL News » 2012 News

2012 News


December 2012

Successes of PBL TEC Scheme: The Figures Speak for Themselves

Now in its tenth year of operation, PBL's TEC Scheme continues to be an extremely successful route for promoting new plant bioscience innovations to industry. In the past three years alone, PBL has offered through the scheme 25 new innovations from 17 different public research institutions in 8 different countries around the world. These include innovations offered by PBL on behalf of INRA Transfert, the technology transfer organisation of the French national agricultural research organisation, INRA. Since January 2010, 37 evaluation licences have been taken by the industry members of the TEC Scheme. Nine of these evaluation agreements also included options to obtain a commercial licence at a later date. Also over the same period, 15 commercial licences have been signed by PBL for technologies promoted through the TEC Scheme, which remains extremely popular with the plant technology industry.

For details of the PBL TEC Scheme, please click here.

Back to top


November 2012

Growing Portfolio of Patents in Biocontrol Area

PBL has recently achieved the grant of various patents from its biocontrol technologies portfolio. While the first patent for the cis-jasmone technology from Rothamsted Research was granted in 2005 (together with grants in Europe and Canada in the same year), the newly granted US Patent No. 8,221,736 extends the scope of the patent cover. In addition the synergist technology (also from RRes) that supports the cis-jasmone technology will grant in the US in the next few months. 

In addition good progress has been made with the jasmonic acid seed treatment technology from Lancaster University. Patents covering the technology have now been granted in the US, Mexico and New Zealand and is shortly also going to be granted in Australia.

For more information, please contact Dr Lars von Borcke.

Back to top


October 2012

PBL Awarded Further US Patent on Short RNAi Molecules: US 8,299,235

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 8,299,235 with fundamental claims directed to compositions to effect gene silencing.

Please click here to read article in full, and here for a link to the Short RNA section on our website.

For licensing enquiries, please contact Dr Lars von Borcke.  All other enquiries to info@pbltechnology.com.

Back to top


October 2012

Plant-Made Protein Platform: PBL and OBP Enter Licence for Animal Health Applications

In October 2012, PBL and OBP (Onderstepoort Biological Products SOC Limited) signed a research and development licence for OBP to use the HT-CPMV system developed by George Lomonossoff and Frank Sainsbury at the John Innes Centre to develop vaccines for use in important animal health applications. Previous tests have already shown the successful vaccination of sheep with a blue tongue virus vaccine. The agreement includes the option to obtain a commercial licence, if the development phase is successful. 

For more information, please contact Dr Lars von Borcke

Back to top


October 2012

PBL in China: PBL to Promote New Technology from IGDB, Beijing

In 2010 we announced our technology development partnerships with the Jilin Academy of Agricultural Sciences (JAAS) and the Institute of Botany, Chinese Academy of Sciences (IB-CAS), under which these partners will make and test transgenic crop plants containing technologies from PBL's portfolio. In a further new direction, PBL is delighted to announce taking on our first new technology invented in a Chinese research institution. In October, PBL started marketing a new plant biotechnology innovation from one of the leading Chinese Academy of Sciences institutes, the Institute of Genetics and Developmental Biology (IGDB). The new technology has already been well received by the international agricultural biotechnology industry. 

For more information, please contact Dr Jan Chojecki.

Back to top


September 2012

PBL Awarded Two Further US Patents on RNAi: US 8,258,285 & US 8,263,569

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.

Please click here to read article in full, and here for a link to the Short RNA section on our website.

For licensing enquiries, please contact Dr Lars von Borcke.  All other enquiries to info@pbltechnology.com.

 

Back to top


September 2012

Funding Boost for Beneforté Broccoli

The world’s largest prostate cancer charity is to fund a UK study of the protective effects of broccoli consumption.

For more information, please click here for the full article, or contact Dr Jan Chojecki.


Back to top


May 2012

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi Patent

Plant Bioscience Limited (PBL) is pleased to announce that they have entered into a licensing agreement with Alnylam Pharmaceuticals, Inc (Nasdaq: ALNY), a leading RNAi therapeutics company. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (US Patent No. 8,097,710) for use in the field of human therapeutics. 

Please click here to read article in full, and here for a link to the Short RNA section on our website.

For more information, please contact Dr Lars von Borcke.

Back to top


March 2012

CONGRATULATIONS to Prof George Lomonossoff

Prof George Lomonossoff has been named BBSRC Innovator of the Year 2012, for his innovations for his work that has led to a plant-based production system for manufacturing proteins.

The system (CPMV and CPMV-HT Protein Expression) is faster than current methods and so it offers an extremely effective way of making proteins such as vaccines rapidly, as needs arise. His work is already being used by Medicago, a Canadian biotechnology company, to develop a vaccine for the H5N1 avian influenza virus under licence from PBL.

Please click here to read article in full.

For more information on these technologies, please contact Dr Lars von Borcke.

Back to top


January 2012

PBL Awarded Pioneering US Patent on RNAi: US 8,097,710

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide range of organisms, including in plants and humans.

To see the full press release, please click here, or for a link to the Short RNA section on our website, please click here.

For licensing enquiries, please contact Dr Lars von Borcke.  All other enquiries to info@pbltechnology.com.

Back to top


January 2012

PBL Commercialisation Activity Highlighted in BBSRC Impact Report

4 January 2012: Today, the Biotechnology and Biological Sciences Research Council (BBSRC) publishes its Impact Report 2011. The report details BBSRC's on-going efforts to ensure that BBSRC-funded research in basic biology can be fully exploited to deliver economic and social benefits for the UK. 

The report picks out a number of major achievements from 2010 - 2011 and in particular highlights the new variety of Broccoli, called Beneforté, developed with funding from BBSRC and commercialised though PBL, plus PBL's licence agreement with Dow AgroSciences in respect of crop root hair enhancement technology from John Innes Centre. The report also cites the progress of Procarta Biosystems Limited, a PBL-assisted spin-out from John Innes Centre. All of the UK's research councils publish Impact Reports today. 

Minister for Universities and Science David Willetts said: "These reports demonstrate that the UK is a world leader in science and research. From the development of groundbreaking new treatments to studies that shape public policy and improve lives, the significant economic and societal impact of the UK research base is extremely impressive."


Back to top


News Archive:
Latest News
2017 News
2016 News
2015 News
2014 News
2013 News
2012 News
2011 News
2010 News
2009 News
2008 News
2007 News
2006 News
2005 News
2004 News
2003 News
2002 News
2001 News
2000 News

Back to top